This move is archived. Current quotes and coverage live on the stock page.
Get CRDL alerts:
Cardiol Therapeutics Inc Class A saw a notable increase, closing up 4.08% in the latest trading session.
In a positive turn for investors, Cardiol Therapeutics Inc Class A (CRDL.TO) rose by 4.08% today, closing at CA$1.53. This increase comes as the company makes progress in its clinical trials and strategic efforts to grow its market presence.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$369.16M
52W high
$3.23
52W low
$1.23
1W change
-7.05%
Beta
0.61
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 116.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+116.6% Upside
Current Price
C$2.77
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
80.6%
Annualized
90-Day Vol
61.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$3.31
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.94 | C$2.23 โ C$3.88 |
| 60 trading days | C$3.12 | C$2.11 โ C$4.62 |
| 90 trading days | C$3.31 | C$2.05 โ C$5.36 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The recent performance of Cardiol Therapeutics signals potential growth in the biotech sector, especially as the company advances its clinical programs and connects with the investment community.
4.08% Increase in Stock Price
Cardiol Therapeutics Inc Class A's stock climbed to CA$1.53, reflecting investor optimism amid ongoing clinical developments.
Bull case
The recent rise in Cardiol's stock price shows growing investor confidence, especially after the acceptance of its Phase II MAvERIC results for publication in a respected journal. This could boost the companyโs credibility and attract more investment.
Bear case
Even with the positive movement, investors should stay cautious. Cardiol Therapeutics has yet to establish a steady revenue stream, and the biotech sector can be unpredictable, heavily influenced by the outcomes of clinical trials and overall market sentiment.
Advertisement
Recent Developments Fueling Growth
Cardiol Therapeutics recently announced that the results from its Phase II MAvERIC trial were accepted for publication in the Journal of the American Heart Association. This is a significant milestone that could enhance the company's visibility and credibility in the medical community, potentially drawing in more investors. Additionally, expanding its U.S. MAVERIC Phase III trial network indicates growing interest in its key programs, which could further boost stock performance. For more details, visit our Cardiol Therapeutics stock page.
Market Confidence and Future Prospects
The rise in Cardiol's stock price reflects a broader confidence in the biotech sector, especially as companies like Cardiol continue to innovate. Investors should consider the implications of ongoing clinical trials and the potential for future partnerships or financing rounds. As Cardiol Therapeutics works to extend its cash runway and develop its product pipeline, the stock may offer growth opportunities. Keep an eye on updates via our CRDL.TO page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
